Skip to main content

Advertisement

SpringerLink
Log in

Prognostic and Predictive Factors in the Targeted Therapy Era: Filling in the Blanks

  • Clinical Trial Report
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Motzer RJ, Mazumdar M, Bacik J, et al.: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999, 17:2530–2540.

    CAS  PubMed  Google Scholar 

  2. Motzer RJ, Bacik J, Murphy BA, et al.: Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002, 20:289–296.

    Article  CAS  PubMed  Google Scholar 

  3. Huang D, Ding Y, Zhou M, et al.: Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 2010, 70:1063–1071.

    Article  CAS  PubMed  Google Scholar 

  4. Tsavachidou-Fenner D, Tannir N, Tamboli P, et al.: Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma. Ann Oncol 2010 Jan 20 (Epub ahead of print).

  5. Klatte T, Rao PN, de Martino M, et al.: Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. J Clin Oncol 2009, 27:746–753.

    Article  PubMed  Google Scholar 

  6. Schneider BP, Wang M, Radovich M, et al.: Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008, 26:4672–4678.

    Article  CAS  PubMed  Google Scholar 

  7. Shojaei F, Wu X, Malik AK, et al.: Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol 2007, 25:911–920.

    Article  CAS  PubMed  Google Scholar 

  8. Zurita AJ, Jonasch E, Wu HK, et al.: Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma. Cancer 2009, 115(10 Suppl):2346–2354.

    Article  CAS  PubMed  Google Scholar 

  9. Jensen TO, Schmidt H, Moller HJ, et al.: Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma. J Clin Oncol 2009, 27:3330–3337.

    Article  PubMed  Google Scholar 

Download references

Disclosure

Dr. Jonasch is a consultant for Pfizer Oncology, Genentech, and Bayer, received research funding from Pfizer Oncology and Genentech, and was on the speakers’ bureau for Novartis Oncology.

Author information

Authors and Affiliations

  1. GU Medical Oncology, The University of Texas, Anderson Cancer Center, Department of Genitourinary Medical Oncology, Unit 1374, PO Box 301439, Houston, TX, 77230-1439, USA

    Eric Jonasch

Authors
  1. Eric Jonasch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eric Jonasch.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jonasch, E. Prognostic and Predictive Factors in the Targeted Therapy Era: Filling in the Blanks. Curr Oncol Rep 12, 143–145 (2010). https://doi.org/10.1007/s11912-010-0098-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-010-0098-z

Keywords

Search

Navigation